What it is
KPV is a very short peptide (three amino acids) taken from the end of alpha-MSH, a natural hormone that calms inflammation.
In lab studies it appears to reduce inflammatory signals inside cells. It is being explored for gut inflammation and skin conditions.
US regulatory status
Not FDA-approved. In April 2026 the FDA removed it from its Category 2 list of compounding substances with safety concerns, and in July 2026 an FDA advisory committee voted 8-6 to recommend adding it to the list of substances pharmacies may compound. As of October 2026 that recommendation is not final: it still needs FDA rulemaking, a proposed interim access policy was under White House review, and it remains an unapproved drug.
What the research shows
Research is almost entirely in cells and animals, especially mouse models of colitis. There are no published human clinical trials showing KPV works or is safe for gut or skin conditions.
How it is given
Oral capsule or subcutaneous injection (unapproved)
Commonly reported side effects
- Injection site reactions
- Stomach upset (oral use)
- No reliable human safety data
- Risk of contaminated or mislabeled products
Questions to ask your provider
- What does the research really show about KPV in humans?
- Are there FDA-approved treatments for my goal that have stronger evidence?
- What are the risks of products labeled "research use only," and how would I know what is really in them?